Carmela Mannarelli

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Journal: NEJM evidence

Published: February 06, 2024

Diagnostic and therapeutic challenges in mast cell sarcoma.

Diagnostic and therapeutic challenges in mast cell sarcoma.

Journal: American journal of hematology

Published: November 13, 2022

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.

Journal: Blood cancer journal

Published: September 09, 2022

SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.

SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates.

Journal: American journal of hematology

Published: June 20, 2022

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.

Journal: Blood cancer journal

Published: March 30, 2022

Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis.

Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis.

Journal: The Journal of allergy and clinical immunology

Published: March 21, 2022

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.

Journal: American journal of hematology

Published: February 17, 2022

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.

Journal: Blood cancer journal

Published: October 19, 2021

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.

Journal: Blood advances

Published: October 13, 2021

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.

Journal: American journal of hematology

Published: July 03, 2021

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.

Journal: Blood advances

Published: October 21, 2020

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Journal: The Lancet. Haematology

Published: September 04, 2020

Showing 1-12 of 42

Last Updated: 09/26/2026